NCT07027072View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Mild Cognitive Impairment (MCI)Mild DementiaAlzheimer's Disease
Interventions
DRUG

KDS2010

KDS2010 will be administered orally once daily, two tablets per day, for 24 weeks. Dosage will be either 60 mg or 120 mg depending on the assigned group.

DRUG

Placebo

Placebo matching the investigational product in appearance but containing no active ingredient, administered orally once daily, two tablets per day, for 24 weeks.

Trial Locations (8)

11923

RECRUITING

Hanyang University Guri Hospital, Guri-si

16247

RECRUITING

The Catholic University of Korea St. Vincent's Hospital, Suwon

16499

RECRUITING

Ajou University Hospital, Suwon

21565

RECRUITING

Gachon University Gil Medical Center, Incheon

61469

RECRUITING

Chonnam National Unversity Hospital, Gwangju

04763

RECRUITING

Hanyang University Seoul Hospital, Seoul

05030

RECRUITING

Konkuk University Medical Center, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

All Listed Sponsors
lead

NeuroBiogen Co., Ltd

INDUSTRY